<h3>領取 TipRanks 高級版 70% 折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，最大化您的投資組合潛力</li>
</ul>
<p>HC Surgical Specialists Ltd ( (SG:1B1) ) 的公告現已發佈。</p>
<p>HC Surgical Specialists 報告截至 2025 年 11 月 30 日的六個月收入為 978 萬新元，同比略微下降 1.6%，而歸屬於股東的利潤增長了 17.5%，達到 397 萬新元，每股收益增加至 2.59 新加坡分。更強的底線主要得益於非經營性收益，包括金融資產公允價值變動的更高收益，以及沒有前一年衍生金融工具的公允價值損失和關聯企業的視同處置損失，董事會宣佈每普通股派發 0.009 新元的中期股息，強調儘管經營表現平平，仍持續回報股東。</p>
<p>(SG:1B1) 股票的最新分析師評級為買入，目標價為 0.50 新元。要查看 HC Surgical Specialists Ltd 股票的完整分析師預測列表，請參見 SG:1B1 股票預測頁面。</p>
<p><strong>關於 HC Surgical Specialists Ltd 的更多信息</strong></p>
<p>HC Surgical Specialists Limited 是一家在新加坡上市的醫療集團，專注於醫療和外科服務行業。該公司及其子公司專注於提供專業的外科護理，特別是在新加坡本地市場。</p>
<p><strong>平均交易量：</strong> 44,981</p>
<p><strong>技術情緒信號：</strong> 買入</p>
<p><strong>當前市值：</strong> 5537 萬新元</p>
<p>在 TipRanks 的股票分析頁面瞭解更多關於 1B1 股票的信息。</p>

<p>HC Surgical Specialists Ltd 報告稱，截至 2025 年 11 月 30 日的六個月內，歸屬於股東的利潤增長了 17.5%，達到 397 萬新元，儘管收入略微下降了 1.6%，降至 978 萬新元。利潤增長主要歸因於非運營性收益。公司宣佈每股派發中期股息 0.009 新元。分析師對該股票給予 “買入” 評級，目標價為 0.50 新元。HC Surgical Specialists 在新加坡的醫療和外科服務行業運營，市值為 5537 萬新元</p>

<h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>領取 TipRanks 高級版 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，最大化您的投資組合潛力</li>
</ul>
</div><p>An announcement from HC Surgical Specialists Ltd ( (SG:1B1) ) is now available.</p>
<div class="lb-trans"><p>HC Surgical Specialists Ltd ( (SG:1B1) ) 的公告現已發佈。</p>
</div><p>HC Surgical Specialists reported revenue of S$9.78 million for the six months ended 30 November 2025, slightly down 1.6% year-on-year, while profit attributable to shareholders rose 17.5% to S$3.97 million and earnings per share increased to 2.59 Singapore cents. The stronger bottom line was driven mainly by non-operational gains, including a higher fair value gain on financial assets at fair value through profit or loss and the absence of prior-year fair value losses on derivative financial instruments and losses from deemed disposal in an associate, and the board declared an interim dividend of S$0.009 per ordinary share, underscoring continued shareholder returns despite flat operating performance.</p>
<div class="lb-trans"><p>HC Surgical Specialists 報告截至 2025 年 11 月 30 日的六個月收入為 978 萬新元，同比略微下降 1.6%，而歸屬於股東的利潤增長了 17.5%，達到 397 萬新元，每股收益增加至 2.59 新加坡分。更強的底線主要得益於非經營性收益，包括金融資產公允價值變動的更高收益，以及沒有前一年衍生金融工具的公允價值損失和關聯企業的視同處置損失，董事會宣佈每普通股派發 0.009 新元的中期股息，強調儘管經營表現平平，仍持續回報股東。</p>
</div><p>The most recent analyst rating on (SG:1B1) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on HC Surgical Specialists Ltd stock, see the SG:1B1 Stock Forecast page.</p>
<div class="lb-trans"><p>(SG:1B1) 股票的最新分析師評級為買入，目標價為 0.50 新元。要查看 HC Surgical Specialists Ltd 股票的完整分析師預測列表，請參見 SG:1B1 股票預測頁面。</p>
</div><p><strong>More about HC Surgical Specialists Ltd</strong></p>
<div class="lb-trans"><p><strong>關於 HC Surgical Specialists Ltd 的更多信息</strong></p>
</div><p>HC Surgical Specialists Limited is a Catalist-listed healthcare group in Singapore that operates in the medical and surgical services industry. The company, together with its subsidiaries, focuses on providing specialist surgical care, particularly in the local Singapore market.</p>
<div class="lb-trans"><p>HC Surgical Specialists Limited 是一家在新加坡上市的醫療集團，專注於醫療和外科服務行業。該公司及其子公司專注於提供專業的外科護理，特別是在新加坡本地市場。</p>
</div><p><strong>Average Trading Volume:</strong> 44,981</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 44,981</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技術情緒信號：</strong> 買入</p>
</div><p><strong>Current Market Cap:</strong> S$55.37M</p>
<div class="lb-trans"><p><strong>當前市值：</strong> 5537 萬新元</p>
</div><p>Learn more about 1B1 stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析頁面瞭解更多關於 1B1 股票的信息。</p>
</div>

HC Surgical Specialists 因投資收益增加提升了半年利潤，並宣佈了中期股息